Psychological co-morbidities in COPD: Targeting systemic inflammation, a benefit for both?

[1]  Yi Lin,et al.  The impact of depression and anxiety on quality of life in Chinese cancer patient-family caregiver dyads, a cross-sectional study , 2018, Health and Quality of Life Outcomes.

[2]  Xingchun Gou,et al.  Drug development for Alzheimer’s disease: review , 2018, Journal of drug targeting.

[3]  L. Tariq,et al.  Adherence to COPD treatment in Turkey and Saudi Arabia: results of the ADCARE study , 2018, International journal of chronic obstructive pulmonary disease.

[4]  Y. Hiasa,et al.  Cigarette smoking is a risk factor for the onset of fatty liver disease in nondrinkers: A longitudinal cohort study , 2018, PloS one.

[5]  Z. Savin,et al.  Smoking and the intestinal microbiome , 2018, Archives of Microbiology.

[6]  A. Blokland,et al.  Acute administration of roflumilast enhances immediate recall of verbal word memory in healthy young adults , 2018, Neuropharmacology.

[7]  Yongqiang Yu,et al.  Alterations of the default mode network and cognitive impairments in patients with chronic obstructive pulmonary disease , 2018, International journal of chronic obstructive pulmonary disease.

[8]  J. Clemente,et al.  The role of the gut microbiome in systemic inflammatory disease , 2018, British Medical Journal.

[9]  P. Ren,et al.  The relationship between cognitive function and arterial partial pressure O2 in patients with COPD , 2018, Medicine.

[10]  K. Padala,et al.  Association of chronic obstructive pulmonary disease with mild cognitive impairment and dementia , 2017, Current opinion in pulmonary medicine.

[11]  A. Keshavarzian,et al.  Gut–brain and brain–gut axis in Parkinson's disease models: Effects of a uridine and fish oil diet , 2017, Nutritional neuroscience.

[12]  Á. Gil,et al.  Effect of omega-3 fatty acids on cognition: an updated systematic review of randomized clinical trials , 2018, Nutrition reviews.

[13]  A. Keshavarzian,et al.  The gut‐brain axis in Parkinson's disease: Possibilities for food‐based therapies , 2017, European journal of pharmacology.

[14]  K. Blennow,et al.  24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial , 2017, The Lancet Neurology.

[15]  P. Poole,et al.  Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. , 2017, The Cochrane database of systematic reviews.

[16]  L. Wood,et al.  Short-chain fatty acids, prebiotics, synbiotics, and systemic inflammation: a systematic review and meta-analysis. , 2017, The American journal of clinical nutrition.

[17]  Marilyn Johnson,et al.  The impact of cognitive impairment on self-management in chronic obstructive pulmonary disease: A systematic review. , 2017, Respiratory medicine.

[18]  T. Furukawa,et al.  Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis , 2017 .

[19]  R. Maestri,et al.  COPD patients’ self-reported adherence, psychosocial factors and mild cognitive impairment in pulmonary rehabilitation , 2017, International journal of chronic obstructive pulmonary disease.

[20]  Thomas R. Barrick,et al.  White matter lesions characterise brain involvement in moderate to severe chronic obstructive pulmonary disease, but cerebral atrophy does not , 2017, BMC Pulmonary Medicine.

[21]  E. Wouters,et al.  A randomized clinical trial investigating the efficacy of targeted nutrition as adjunct to exercise training in COPD , 2017, Journal of cachexia, sarcopenia and muscle.

[22]  S. Bhar,et al.  The impact of telephone-delivered cognitive behaviour therapy and befriending on mood disorders in people with chronic obstructive pulmonary disease: A randomized controlled trial. , 2017, British journal of health psychology.

[23]  D. Brooks,et al.  Chronic Pain in People With Chronic Obstructive Pulmonary Disease: Prevalence, Clinical and Psychological Implications. , 2017, Chronic obstructive pulmonary diseases.

[24]  E. Wouters,et al.  The Impact of Cognitive Impairment on Efficacy of Pulmonary Rehabilitation in Patients With COPD. , 2017, Journal of the American Medical Directors Association.

[25]  I. Leroi,et al.  Cognitive Impairment in Chronic Obstructive Pulmonary Disease and Chronic Heart Failure: A Systematic Review and Meta-analysis of Observational Studies. , 2017, Journal of the American Medical Directors Association.

[26]  J. Wedzicha,et al.  Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary , 2017, European Respiratory Journal.

[27]  A. Kraneveld,et al.  Promising Effects of Neurorestorative Diets on Motor, Cognitive, and Gastrointestinal Dysfunction after Symptom Development in a Mouse Model of Parkinson's Disease , 2017, Front. Aging Neurosci..

[28]  J. Wedzicha,et al.  Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. , 2017, American journal of respiratory and critical care medicine.

[29]  K. Budden,et al.  Microbiome effects on immunity, health and disease in the lung , 2017, Clinical & translational immunology.

[30]  C. Yeh,et al.  Association Between Antipsychotic Agents and Risk of Acute Respiratory Failure in Patients With Chronic Obstructive Pulmonary Disease , 2017, JAMA psychiatry.

[31]  L. Hogarth,et al.  Cigarette smoking and depression comorbidity: systematic review and proposed theoretical model , 2017, Addiction.

[32]  A. Heerschap,et al.  Butyrate restores HFD-induced adaptations in brain function and metabolism in mid-adult obese mice , 2017, International Journal of Obesity.

[33]  K. Lavoie,et al.  Recognition, diagnosis, and treatment of cognitive and psychiatric disorders in patients with COPD , 2017, International journal of chronic obstructive pulmonary disease.

[34]  E. Sapey,et al.  Oxidative Stress in COPD: Sources, Markers, and Potential Mechanisms , 2017, Journal of clinical medicine.

[35]  T. Dinan,et al.  Kynurenine pathway metabolism and the microbiota-gut-brain axis , 2017, Neuropharmacology.

[36]  E. Wouters,et al.  Domain-specific cognitive impairment in patients with COPD and control subjects , 2016, International journal of chronic obstructive pulmonary disease.

[37]  H. Majid,et al.  Anxiety and Depression in COPD Patients , 2017 .

[38]  CHRONIC OBSTRUCTIVE PULMONARY , 2017 .

[39]  I. Nordhus,et al.  Non-pharmacological Interventions to Manage Depression and Anxiety Associated with Chronic Respiratory Diseases: Cognitive Behavioral Therapy and Others , 2017 .

[40]  E. Dooley,et al.  Depression and Anxiety Across the Age Spectrum , 2017 .

[41]  A. Sharafkhaneh,et al.  Overview of Psychological Considerations in the Management of Patients with Chronic Respiratory Conditions , 2017 .

[42]  G. Grosso,et al.  Dietary n-3 PUFA, fish consumption and depression: A systematic review and meta-analysis of observational studies. , 2016, Journal of affective disorders.

[43]  T. Dinan,et al.  Psychobiotics and the Manipulation of Bacteria–Gut–Brain Signals , 2016, Trends in Neurosciences.

[44]  P. Langenberg,et al.  Adherence to Maintenance Medications among Older Adults with Chronic Obstructive Pulmonary Disease. The Role of Depression. , 2016, Annals of the American Thoracic Society.

[45]  B. Celli,et al.  The impact of depression and anxiety on never-smokers COPD patients , 2016 .

[46]  M. Hsieh,et al.  Chronic obstructive pulmonary disease and anxiety disorders: a nationwide population-based study in Taiwan. , 2016, General hospital psychiatry.

[47]  Manisha N. Patel.  Targeting Oxidative Stress in Central Nervous System Disorders. , 2016, Trends in pharmacological sciences.

[48]  M. Campos,et al.  Chronic electronic cigarette exposure in mice induces features of COPD in a nicotine-dependent manner , 2016, Thorax.

[49]  A. Diaz,et al.  Prevalence of depression in COPD: A systematic review and meta-analysis of controlled studies. , 2016, Respiratory medicine.

[50]  A. Jačan,et al.  Cognitive impairment by antibiotic-induced gut dysbiosis: Analysis of gut microbiota-brain communication , 2016, Brain, Behavior, and Immunity.

[51]  J Licinio,et al.  From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways , 2016, Molecular Psychiatry.

[52]  J. Yim,et al.  Effect of inhaled drugs on anxiety and depression in patients with chronic obstructive pulmonary disease: a prospective observational study , 2016, International journal of chronic obstructive pulmonary disease.

[53]  T. Dinan,et al.  Food for thought: The role of nutrition in the microbiota-gut–brain axis , 2016 .

[54]  J. Vestbo,et al.  Long-term Course of Depression Trajectories in Patients With COPD: A 3-Year Follow-up Analysis of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints Cohort. , 2016, Chest.

[55]  A. Blaszczyk,et al.  COPD Exacerbation and Cholinesterase Therapy in Dementia Patients. , 2016, The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.

[56]  Y. Kuo,et al.  Association of Psychological Disorders With 30-Day Readmission Rates in Patients With COPD. , 2016, Chest.

[57]  M. Miravitlles,et al.  Cognitive status among patients with chronic obstructive pulmonary disease , 2016, International journal of chronic obstructive pulmonary disease.

[58]  Benjamin M. Smith,et al.  Understanding the impact of second-hand smoke exposure on clinical outcomes in participants with COPD in the SPIROMICS cohort , 2016, Thorax.

[59]  A. von Leupoldt,et al.  Structural Brain Changes in Patients With COPD. , 2016, Chest.

[60]  M. P. Francino,et al.  Antibiotics and the Human Gut Microbiome: Dysbioses and Accumulation of Resistances , 2016, Front. Microbiol..

[61]  R. D'Incà,et al.  Intestinal Permeability in Inflammatory Bowel Disease: Pathogenesis, Clinical Evaluation, and Therapy of Leaky Gut , 2015, Mediators of inflammation.

[62]  A. Lindén,et al.  Hypoxia associated with increased systemic concentrations of MPO and NE during exacerbations of COPD , 2015 .

[63]  T. Halvorsen,et al.  Benzodiazepine use in COPD: empirical evidence from Norway , 2015, International journal of chronic obstructive pulmonary disease.

[64]  P. de Jonge,et al.  Reporting Bias in Clinical Trials Investigating the Efficacy of Second-Generation Antidepressants in the Treatment of Anxiety Disorders: A Report of 2 Meta-analyses. , 2015, JAMA psychiatry.

[65]  P. Calder.  Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. , 2015, Biochimica et biophysica acta.

[66]  J. Dodd,et al.  Lung disease as a determinant of cognitive decline and dementia , 2015, Alzheimer's Research & Therapy.

[67]  Andrew H. Miller,et al.  The role of inflammation in depression: from evolutionary imperative to modern treatment target , 2015, Nature Reviews Immunology.

[68]  M. D'Andrea.  The Alpha 7 Nicotinic Acetylcholine Receptor , 2015 .

[69]  C. Bucca,et al.  Severe vitamin D deficiency is associated with frequent exacerbations and hospitalization in COPD patients , 2014, Respiratory Research.

[70]  O. Mors,et al.  Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. , 2014, JAMA psychiatry.

[71]  A. Yohannes.  Cognitive impairment and risk for disability in chronic obstructive pulmonary disease. , 2014, Annals of the American Thoracic Society.

[72]  C. Richardson,et al.  Chronic obstructive pulmonary disease, cognitive impairment, and development of disability: the health and retirement study. , 2014, Annals of the American Thoracic Society.

[73]  I. Yang,et al.  Anxiety and depression-Important psychological comorbidities of COPD. , 2014, Journal of thoracic disease.

[74]  J. Suls,et al.  How robust is the association between smoking and depression in adults? A meta-analysis using linear mixed-effects models. , 2014, Addictive behaviors.

[75]  T. Furukawa,et al.  Azapirones versus placebo for panic disorder in adults. , 2014, The Cochrane database of systematic reviews.

[76]  D. Ditor,et al.  The common inflammatory etiology of depression and cognitive impairment: a therapeutic target , 2014, Journal of Neuroinflammation.

[77]  G. Alexopoulos,et al.  Depression and anxiety in patients with COPD , 2014, European Respiratory Review.

[78]  H. Jónsdóttir,et al.  The relationships between smoking and anxiety and depression in people with COPD – Implications for smoking cessation treatment for people with COPD , 2014 .

[79]  B. Timar,et al.  Cognitive Impairment in Chronic Obstructive Pulmonary Disease , 2014, PloS one.

[80]  J. Zhao,et al.  Interaction of Depressive and Anxiety Symptoms on the Mortality of Patients with COPD: A Preliminary Study , 2014, COPD.

[81]  G. Alexopoulos,et al.  Pharmacological Treatment of Depression in Older Patients with Chronic Obstructive Pulmonary Disease: Impact on the Course of the Disease and Health Outcomes , 2014, Drugs & Aging.

[82]  Xiao-tong Wang,et al.  Efficacy of Lovastatin on Learning and Memory Deficits Caused by Chronic Intermittent Hypoxia-Hypercapnia: Through Regulation of NR2B-Containing NMDA Receptor-ERK Pathway , 2014, PloS one.

[83]  P. Gao,et al.  Impact of regional white matter lesions on cognitive function in subcortical vascular cognitive impairment , 2014, Neurological research.

[84]  J. O'Donnell,et al.  Novel Therapeutic Targets in Depression and Anxiety: Antioxidants as a Candidate Treatment , 2014, Current neuropharmacology.

[85]  Ju-Sheng Zheng,et al.  Effect of Marine-Derived n-3 Polyunsaturated Fatty Acids on C-Reactive Protein, Interleukin 6 and Tumor Necrosis Factor α: A Meta-Analysis , 2014, PloS one.

[86]  Bill Y. Lin,et al.  Formoterol, a Long-Acting β2 Adrenergic Agonist, Improves Cognitive Function and Promotes Dendritic Complexity in a Mouse Model of Down Syndrome , 2014, Biological Psychiatry.

[87]  E. Wouters,et al.  Disturbed intestinal integrity in patients with COPD: effects of activities of daily living. , 2014, Chest.

[88]  P. Kamphuis,et al.  Targeting synaptic dysfunction in Alzheimer's disease by administering a specific nutrient combination. , 2013, Journal of Alzheimer's disease : JAD.

[89]  E. Wouters,et al.  Quality of dietary intake in relation to body composition in patients with chronic obstructive pulmonary disease eligible for pulmonary rehabilitation , 2014, European Journal of Clinical Nutrition.

[90]  E. Chang,et al.  ROS and Brain Diseases: The Good, the Bad, and the Ugly , 2013, Oxidative medicine and cellular longevity.

[91]  E. Russo,et al.  Corticosteroid-related central nervous system side effects , 2013, Journal of pharmacology & pharmacotherapeutics.

[92]  G. Tzortzis,et al.  Prebiotic feeding elevates central brain derived neurotrophic factor, N-methyl-d-aspartate receptor subunits and d-serine☆ , 2013, Neurochemistry International.

[93]  The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer’s disease , 2013, Alzheimer's Research & Therapy.

[94]  John F. Cryan,et al.  Psychobiotics: A Novel Class of Psychotropic , 2013, Biological Psychiatry.

[95]  L. Oldervoll,et al.  Impact of symptoms of anxiety and depression on COPD Assessment Test scores , 2013, European Respiratory Journal.

[96]  L. Joosten,et al.  Effects of Specific Multi-Nutrient Enriched Diets on Cerebral Metabolism, Cognition and Neuropathology in AβPPswe-PS1dE9 Mice , 2013, PloS one.

[97]  Barbara M. Bakker,et al.  The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism , 2013, Journal of Lipid Research.

[98]  P. Dederen,et al.  Impact of a multi-nutrient diet on cognition, brain metabolism, hemodynamics, and plasticity in apoE4 carrier and apoE knockout mice , 2013, Brain Structure and Function.

[99]  R. Charlton,et al.  Cognitive dysfunction in patients hospitalized with acute exacerbation of COPD. , 2013, Chest.

[100]  P. Kirkham,et al.  Oxidative stress in COPD. , 2013, Chest.

[101]  A. Schols,et al.  Characterization of the inflammatory and metabolic profile of adipose tissue in a mouse model of chronic hypoxia. , 2013, Journal of applied physiology.

[102]  M. Lainscak,et al.  Chronic obstructive pulmonary disease patient journey: hospitalizations as window of opportunity for extra-pulmonary intervention , 2013, Current opinion in clinical nutrition and metabolic care.

[103]  P. Rochon,et al.  Benzodiazepine Use among Older Adults with Chronic Obstructive Pulmonary Disease , 2013, Drugs & Aging.

[104]  P. Kamphuis,et al.  A specific multi-nutrient diet reduces Alzheimer-like pathology in young adult AβPPswe/PS1dE9 mice. , 2012, Journal of Alzheimer's disease : JAD.

[105]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[106]  A. Garthe,et al.  Improved spatial learning strategy and memory in aged Alzheimer AβPPswe/PS1dE9 mice on a multi-nutrient diet. , 2013, Journal of Alzheimer's disease : JAD.

[107]  S. Banni,et al.  Marine Omega-3 Phospholipids: Metabolism and Biological Activities , 2012, International journal of molecular sciences.

[108]  M. Steiner,et al.  Nutritional targets to enhance exercise performance in chronic obstructive pulmonary disease , 2012, Current opinion in clinical nutrition and metabolic care.

[109]  Ruoling Chen,et al.  Association between environmental tobacco smoke exposure and dementia syndromes , 2012, Occupational and Environmental Medicine.

[110]  M. Blaut,et al.  Role of commensal gut bacteria in inflammatory bowel diseases , 2012, Gut microbes.

[111]  Sandy S Chang,et al.  Effect of Coexisting Chronic Obstructive Pulmonary Disease and Cognitive Impairment on Health Outcomes in Older Adults , 2012, Journal of the American Geriatrics Society.

[112]  Yanan Zhu,et al.  Prevalence and correlations with depression, anxiety, and other features in outpatients with chronic obstructive pulmonary disease in China: a cross-sectional case control study , 2012, BMC Pulmonary Medicine.

[113]  Yongmei Liu,et al.  The influence of abdominal visceral fat on inflammatory pathways and mortality risk in obstructive lung disease. , 2012, The American journal of clinical nutrition.

[114]  L. Rasmussen,et al.  Cognitive dysfunction in patients with chronic obstructive pulmonary disease--a systematic review. , 2012, Respiratory medicine.

[115]  Courtney Crim,et al.  Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype , 2012, PloS one.

[116]  N. Vozoris,et al.  Prevalence, risk factors, activity limitation and health care utilization of an obese, population-based sample with chronic obstructive pulmonary disease. , 2012, Canadian respiratory journal.

[117]  A. Fritzsche,et al.  Behavioral Medicine Approaches to Chronic Obstructive Pulmonary Disease , 2012, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

[118]  Meilan K. Han,et al.  Significance of the microbiome in obstructive lung disease , 2012, Thorax.

[119]  A. Beekman,et al.  Association of depressive disorders, depression characteristics and antidepressant medication with inflammation , 2012, Translational Psychiatry.

[120]  B. Harvey,et al.  Metabotropic and ionotropic glutamate receptors as neurobiological targets in anxiety and stress-related disorders: Focus on pharmacology and preclinical translational models , 2012, Pharmacology Biochemistry and Behavior.

[121]  Cornelis J Stam,et al.  Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. , 2012, Journal of Alzheimer's disease : JAD.

[122]  D. Sheehan,et al.  Generalized anxiety disorder. , 2012, Handbook of clinical neurology.

[123]  G. Wesseling,et al.  Low-grade adipose tissue inflammation in patients with mild-to-moderate chronic obstructive pulmonary disease. , 2011, The American journal of clinical nutrition.

[124]  A. Esterman,et al.  Pharmacological interventions for the treatment of anxiety disorders in chronic obstructive pulmonary disease. , 2011, The Cochrane database of systematic reviews.

[125]  A. von Leupoldt,et al.  Effects of medical and psychological treatment of depression in patients with COPD--a review. , 2011, Respiratory medicine.

[126]  G. Joos,et al.  Chronic Obstructive Pulmonary Disease 1 New insights into the immunology of chronic obstructive pulmonary disease , 2011 .

[127]  A. Kraneveld,et al.  Treatment with specific prebiotics or probiotics prevents the development of lung emphysema in a mouse model of COPD , 2011 .

[128]  A. von Leupoldt,et al.  The impact of anxiety and depression on outcomes of pulmonary rehabilitation in patients with COPD. , 2011, Chest.

[129]  M. Košnik,et al.  Anxiety and Depression during Hospital Treatment of Exacerbation of Chronic Obstructive Pulmonary Disease , 2011, The Journal of international medical research.

[130]  Melvyn W B Zhang,et al.  Prevalence of depressive symptoms in patients with chronic obstructive pulmonary disease: a systematic review, meta-analysis and meta-regression. , 2011, General hospital psychiatry.

[131]  Patrick D Mitchell,et al.  Hypoxemia in patients with COPD: cause, effects, and disease progression , 2011, International journal of chronic obstructive pulmonary disease.

[132]  G. Kumar.  Hypoxia. 3. Hypoxia and neurotransmitter synthesis. , 2011, American journal of physiology. Cell physiology.

[133]  Dave Singh,et al.  Biomarkers of systemic inflammation and depression and fatigue in moderate clinically stable COPD , 2011, Respiratory research.

[134]  A. Fischer,et al.  Sodium butyrate improves memory function in an Alzheimer's disease mouse model when administered at an advanced stage of disease progression. , 2011, Journal of Alzheimer's disease : JAD.

[135]  A. Bozek,et al.  The Improvement of Cognitive Functions in Patients with Bronchial Asthma after Therapy , 2010, The Journal of asthma : official journal of the Association for the Care of Asthma.

[136]  Edwin K Silverman,et al.  Characterisation of COPD heterogeneity in the ECLIPSE cohort , 2010, Respiratory research.

[137]  R. Stockley,et al.  Systemic inflammation and comorbidity in COPD: a result of ‘overspill’ of inflammatory mediators from the lungs? Review of the evidence , 2010, Thorax.

[138]  Paul D Blanc,et al.  COPD and cognitive impairment: the role of hypoxemia and oxygen therapy , 2010, International journal of chronic obstructive pulmonary disease.

[139]  Courtney A Miller,et al.  Inhibitors of Class 1 Histone Deacetylases Reverse Contextual Memory Deficits in a Mouse Model of Alzheimer's Disease , 2010, Neuropsychopharmacology.

[140]  T. Omachi,et al.  Influence of anxiety on health outcomes in COPD , 2010, Thorax.

[141]  P. Scheltens,et al.  Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial , 2010, Alzheimer's & Dementia.

[142]  S. Glantz,et al.  Cigarette smoking is a risk factor for Alzheimer's Disease: an analysis controlling for tobacco industry affiliation. , 2010, Journal of Alzheimer's disease : JAD.

[143]  M. Decramer,et al.  Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D-binding gene , 2009, Thorax.

[144]  E. Brown.  Effects of Glucocorticoids on Mood, Memory, and the Hippocampus , 2009, Annals of the New York Academy of Sciences.

[145]  O. Arancio,et al.  Reversal of long-term dendritic spine alterations in Alzheimer disease models , 2009, Proceedings of the National Academy of Sciences.

[146]  P. Bakke,et al.  Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort Study , 2009, European Respiratory Journal.

[147]  L. Dieleman,et al.  Prebiotics in Chronic Intestinal Inflammation , 2009, Inflammatory bowel diseases.

[148]  I. Lang,et al.  Exposure to secondhand smoke and cognitive impairment in non-smokers: national cross sectional study with cotinine measurement , 2009, BMJ : British Medical Journal.

[149]  Andrew H. Miller.  Mechanisms of cytokine-induced behavioral changes: Psychoneuroimmunology at the translational interface , 2009, Brain, Behavior, and Immunity.

[150]  S. McCrone,et al.  Chronic obstructive pulmonary disease, anxiety, and depression: state of the science. , 2009, Heart & lung : the journal of critical care.

[151]  Judy H Cho,et al.  Inflammatory bowel disease. , 2009, The New England journal of medicine.

[152]  Nicola A Hanania,et al.  Anxiety and Depression in COPD: Current Understanding, Unanswered Questions, and Research Needs. , 2008, Chest.

[153]  D. Spina,et al.  PDE4 inhibitors: current status , 2008, British journal of pharmacology.

[154]  P. Calder.  The relationship between the fatty acid composition of immune cells and their function. , 2008, Prostaglandins, leukotrienes, and essential fatty acids.

[155]  Bohan Wang,et al.  Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity? , 2008, British Journal of Nutrition.

[156]  I. Pavord,et al.  Prevalence of inflammatory bowel disease in patients with airways disease. , 2008, Respiratory medicine.

[157]  M. Zvolensky,et al.  Nicotine dependence and mental disorders among adults in the USA: evaluating the role of the mode of administration , 2008, Psychological Medicine.

[158]  F. Granath,et al.  Increased Risk of Both Ulcerative Colitis and Crohn’s Disease in a Population Suffering from COPD , 2008, Lung.

[159]  J. Chen,et al.  Neuroinflammation and disruption in working memory in aged mice after acute stimulation of the peripheral innate immune system , 2008, Brain, Behavior, and Immunity.

[160]  Wang Mu-y.  The metabolic syndrome,inflammation,and risk of cognitive decline in elderly patients with ischemic stroke , 2008 .

[161]  R. Dantzer,et al.  From inflammation to sickness and depression: when the immune system subjugates the brain , 2008, Nature Reviews Neuroscience.

[162]  A. Bhunia,et al.  Hypoxia and chronic lung disease , 2007, Journal of Molecular Medicine.

[163]  Hongwei Yao,et al.  Future therapeutic treatment of COPD: Struggle between oxidants and cytokines , 2007, International journal of chronic obstructive pulmonary disease.

[164]  Kaarin J Anstey,et al.  Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies. , 2007, American journal of epidemiology.

[165]  L. Ulloa,et al.  The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation , 2007, British journal of pharmacology.

[166]  Amanda J Lee,et al.  Associations of depression and anxiety with gender, age, health-related quality of life and symptoms in primary care COPD patients. , 2007, Family practice.

[167]  A. Miller,et al.  Endogenous glucocorticoids protect against TNF-alpha-induced increases in anxiety-like behavior in virally infected mice , 2007, Molecular Psychiatry.

[168]  M. A. Kassim.  Dietary modulation of the human colonic microbiota through plant-derived prebiotic compounds , 2007 .

[169]  F. Blasi,et al.  Anxiety and depression in COPD patients: The roles of gender and disease severity. , 2006, Respiratory medicine.

[170]  T. Stage,et al.  Depression in COPD – management and quality of life considerations , 2006, International journal of chronic obstructive pulmonary disease.

[171]  I. Adcock,et al.  Oxidative stress and redox regulation of lung inflammation in COPD , 2006, European Respiratory Journal.

[172]  B. Roozendaal,et al.  Do Corticosteroids Damage the Brain? , 2006, Journal of neuroendocrinology.

[173]  P. Nicoletti,et al.  Novel therapeutic targets , 2006, Neurological Sciences.

[174]  Ian Wilson,et al.  Depression in the patient with COPD , 2006, International journal of chronic obstructive pulmonary disease.

[175]  M. D'Andrea,et al.  Targeting the alpha 7 nicotinic acetylcholine receptor to reduce amyloid accumulation in Alzheimer's disease pyramidal neurons. , 2006, Current pharmaceutical design.

[176]  M. Forlenza,et al.  Increased Serum Levels of 8-Hydroxy-2′-Deoxyguanosine in Clinical Depression , 2006, Psychosomatic medicine.

[177]  F. Rengo,et al.  Drawing impairment predicts mortality in severe COPD. , 2006, Chest.

[178]  Andrew H. Miller,et al.  Cytokines sing the blues: inflammation and the pathogenesis of depression. , 2006, Trends in immunology.

[179]  E. Wouters,et al.  Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. , 2005, Archives of internal medicine.

[180]  Jalpa A Doshi,et al.  Long-term risk for depressive symptoms after a medical diagnosis. , 2005, Archives of internal medicine.

[181]  Mark E Kunik,et al.  Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. , 2005, Chest.

[182]  J. Roca,et al.  Oxidative stress and airway inflammation in severe exacerbations of COPD , 2005, Thorax.

[183]  T. Harris,et al.  The metabolic syndrome, inflammation, and risk of cognitive decline. , 2004, JAMA.

[184]  N. Eiser,et al.  Effect of Treating Depression on Quality-of-Life and Exercise Tolerance in Severe COPD , 2005, COPD.

[185]  Arif Khan,et al.  Study designs and outcomes in antidepressant clinical trials. , 2005, Essential psychopharmacology.

[186]  C. S. Holling,et al.  Regime Shifts, Resilience, and Biodiversity in Ecosystem Management , 2004 .

[187]  A. Newman,et al.  The metabolic syndrome, inflammation, and risk of cognitive decline. , 2004, JAMA.

[188]  Y. Lacasse,et al.  Randomized trial of paroxetine in end-stage COPD. , 2004, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[189]  P. Doraiswamy,et al.  Citalopram and quality of life in lung transplant recipients. , 2004, Psychosomatics.

[190]  I. Orsola,et al.  Drawing impairment predicts mortality in severe COPD. , 2004 .

[191]  C. Pisinger,et al.  Anxiety and depression in patients with chronic obstructive pulmonary disease (COPD). A review , 2004, Nordic journal of psychiatry.

[192]  J. Olney,et al.  Cytotoxic effects of acidic and sulphur containing amino acids on the infant mouse central nervous system , 2004, Experimental Brain Research.

[193]  H. Steinbusch,et al.  Inflammation markers in relation to cognition in a healthy aging population , 2003, Journal of Neuroimmunology.

[194]  M. Stanbrook,et al.  Corticosteroid therapy for patients with acute exacerbations of chronic obstructive pulmonary disease: a systematic review. , 2002, Archives of internal medicine.

[195]  H. Cohen,et al.  Cytokines and Cognition—The Case for A Head‐to‐Toe Inflammatory Paradigm , 2002, Journal of the American Geriatrics Society.

[196]  C. Nemeroff,et al.  Neurobehavioral Effects of Interferon-α in Cancer Patients: Phenomenology and Paroxetine Responsiveness of Symptom Dimensions , 2002, Neuropsychopharmacology.

[197]  K. Coffman.  Psychiatric issues in pulmonary disease. , 2002, The Psychiatric clinics of North America.

[198]  Thomas A M Kramer,et al.  Drug development. , 2002, MedGenMed : Medscape general medicine.

[199]  D. Postma,et al.  Chronic obstructive pulmonary disease. , 2002, Clinical evidence.

[200]  C. V. van Schayck,et al.  Antidepressants in the treatment of patients with COPD: possible associations between smoking cigarettes, COPD and depression , 2001, Thorax.

[201]  A. Yohannes,et al.  A feasibility study of antidepressant drug therapy in depressed elderly patients with chronic obstructive pulmonary disease † , 2001, International journal of geriatric psychiatry.

[202]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[203]  A K Manatunga,et al.  Paroxetine for the prevention of depression induced by high-dose interferon alfa. , 2001, The New England journal of medicine.

[204]  E. Brown,et al.  Mood and Cognitive Changes During Systemic Corticosteroid Therapy. , 2001, Primary care companion to the Journal of clinical psychiatry.

[205]  Health systems: improving performance , 2000 .

[206]  F. Holsboer,et al.  Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1 , 1998, Nature Genetics.

[207]  J. Fawcett,et al.  A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. , 1998, The Journal of clinical psychiatry.

[208]  H. Hoek,et al.  Cocaine as a risk factor for neuroleptic-induced acute dystonia. , 1998, The Journal of clinical psychiatry.

[209]  G. Koob,et al.  Neurobiological Similarities in Depression and Drug Dependence: A Self-Medication Hypothesis , 1998, Neuropsychopharmacology.

[210]  Mark E. Williams,et al.  Diagnosis and treatment of depression in late life. , 1992, The Journal of clinical psychiatry.

[211]  J. Smoller,et al.  Sertraline effects on dyspnea in patients with obstructive airways disease. , 1998, Psychosomatics.

[212]  B. Lebowitz,et al.  Diagnosis and Treatment of Depression in Late Life: Consensus Statement Update , 1997 .

[213]  M. Lye,et al.  Placebo‐controlled treatment trial of depression in elderly physically ill patients , 1997, International journal of geriatric psychiatry.

[214]  W. MacNee,et al.  Systemic oxidative stress in asthma, COPD, and smokers. , 1996, American journal of respiratory and critical care medicine.

[215]  J. Gorman,et al.  Sertraline for chronic obstructive pulmonary disease and comorbid anxiety and mood disorders. , 1995, The American journal of psychiatry.

[216]  G R Gibson,et al.  Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. , 1995, The Journal of nutrition.

[217]  K. Pehrsson,et al.  Effect of protriptyline, 10 mg daily, on chronic hypoxaemia in chronic obstructive pulmonary disease. , 1995, The European respiratory journal.

[218]  C. Miller.  Drugs in development for Alzheimer's disease. , 1993, Geriatric nursing.

[219]  C. Marra,et al.  Chronic obstructive pulmonary disease. An original model of cognitive decline. , 1993, The American review of respiratory disease.

[220]  R. Light,et al.  Effects of buspirone on anxiety levels and exercise tolerance in patients with chronic airflow obstruction and mild anxiety. , 1993, Chest.

[221]  D. Georgopoulos,et al.  Buspirone effect on breathlessness and exercise performance in patients with chronic obstructive pulmonary disease. , 1993, Respiration; international review of thoracic diseases.

[222]  S. Borson,et al.  Improvement in mood, physical symptoms, and function with nortriptyline for depression in patients with chronic obstructive pulmonary disease. , 1992, Psychosomatics.

[223]  T. K. Hunt,et al.  Cigarette smoking decreases tissue oxygen. , 1991, Archives of surgery.

[224]  J. Helzer,et al.  Smoking, smoking cessation, and major depression. , 1990, JAMA.

[225]  A. Gift,et al.  Depression, somatization and steroid use in chronic obstructive pulmonary disease. , 1989, International journal of nursing studies.

[226]  R. Light,et al.  Doxepin treatment of depressed patients with chronic obstructive pulmonary disease. , 1986, Archives of internal medicine.

[227]  C. K. Mahutte,et al.  Effect of desipramine on control of ventilation and depression scores in patients with severe chronic obstructive pulmonary disease , 1985, Psychiatry Research.

[228]  I. Grant,et al.  Neuropsychologic findings in hypoxemic chronic obstructive pulmonary disease. , 1982, Archives of internal medicine.

[229]  J. Blass,et al.  Brain dysfunction in mild to moderate hypoxia. , 1981, The American journal of medicine.

[230]  T. Oppé,et al.  Vitamin D deficiency. , 1979, British medical journal.

[231]  L. Wilhelmsen,et al.  [Smoking as a risk factor]. , 1971, Lakartidningen.

[232]  D. Ferriman.  Corticosteroid therapy. , 1961, Nursing times.